Guard Therapeutics Announces Top-Line Results from Phase 2b POINTER Study
Guard Therapeutics (publ) announced top-line results from the Phase 2b POINTER study, evaluating RMC-035 as a kidney-protective therapy in patients undergoing open-heart surgery.
The study did not meet its primary and key secondary efficacy endpoints.
"The results from the POINTER study are disappointing, given previous findings of efficacy for RMC-035 and the significant unmet medical need in preventing irreversible kidney damage after open-heart surgery," said Tobias Agervald, CEO of Guard Therapeutics.
Despite the disappointing results, Guard Therapeutics remains committed to understanding the study outcome and evaluating next steps.
Author's summary: Guard Therapeutics' RMC-035 fails to meet efficacy endpoints.
More News
- READY, FIRE, AIM: Fly Me to the Moon – Pagosa Daily Post News Events & Video for Pagosa Springs Colorado
- Early TNF Inhibitor Use Improves Outcomes in Nonsystemic JIA
- Lupus Foundation of America Honors Outstanding Achievements in Lupus Research
- Banks’ stampede for deposits to intensify
- Government shutdown threatens CPG brands tied to SNAP and WIC
- Older Patients and Women Bear the Brunt of CTD-ILD Burden
- Kymera Therapeutics, Inc.: Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting
- Comet 3I/ATLAS approaching Sun SOON: Here’s what to expect
- Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis
- Canada’s Lululemon Partners With National Football League